Rift Valley fever virus subunit vaccines confer complete protection against a lethal virus challenge

被引：62

作者：

de Boer, S. M. ^{[1
,2
]}

Kortekaas, J. ^{[1
]}

Antonis, A. F. ^{[1
]}

Kant, J. ^{[1
]}

van Oploo, J. L. ^{[2
]}

Rottier, P. J. M. ^{[2
]}

Moormann, R. J. M. ^{[1
,2
]}

Bosch, B. J. ^{[2
]}

机构：

[1] Univ Wageningen & Res Ctr, Cent Vet Inst, NL-8219 PH Lelystad, Netherlands

[2] Univ Utrecht, Fac Vet Med, Div Virol, Dept Infect Dis & Immunol, NL-3584 CL Utrecht, Netherlands

来源：

VACCINE | 2010年 / 28卷 / 11期

关键词：

Rift Valley fever virus; Virus-like particle; VLP; Subunit vaccine; DIVA; IMMUNOGENIC PROPERTIES; PARTICLES; EXPRESSION; TRANSCRIPTION; ANTIBODIES; ADJUVANTS; RESPONSES; PROTEINS; SYSTEM; HUMANS;

D O I：

10.1016/j.vaccine.2009.12.062

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Rift Valley fever virus (RVFV) is an emerging mosquito-borne virus causing significant morbidity and mortality in livestock and humans. Rift Valley fever is endemic in Africa, but also outside this continent outbreaks have been reported. Here we report the evaluation of two vaccine candidates based on the viral Gn and Gc envelope glycoproteins, both produced in a Drosophila insect cell expression system. Virus-like particles (VLPs) were generated by merely expressing the Gn and Gc glycoproteins. In addition, a soluble form of the Gn ectodomain was expressed and affinity-purified from the insect cell culture supernatant. Both vaccine candidates fully protected mice from a lethal challenge with RVFV. Importantly, absence of the nucleocapsid protein in either vaccine candidate facilitates the differentiation between infected and vaccinated animals using a commercial recombinant nucleocapsid protein-based indirect ELISA. (C) 2010 Elsevier Ltd. All rights reserved.

引用

页码：2330 / 2339

页数：10

共 59 条

[1]

Alley R., 2007, IPCC WGI Fourth Assessment Report

[2]

[Anonymous], 2007, Wkly Epidemiol Rec, V82, P417

[3]

[Anonymous], 2007, Weekly Epidemiological Record, V82, P169

[4] Neutralizing antiviral B cell responses [J].

Bachmann, MF ;

Zinkernagel, RM .

ANNUAL REVIEW OF IMMUNOLOGY, 1997, 15 :235-270

[5] Partial correction of the TH2/TH1 imbalance in neonatal murine responses to vaccine antigens through selective adjuvant effects [J].

Barrios, C ;

Brandt, C ;

Berney, M ;

Lambert, PH ;

Siegrist, CA .

EUROPEAN JOURNAL OF IMMUNOLOGY, 1996, 26 (11) :2666-2670

[6] Investigation of several selected adjuvants regarding their efficacy and side effects for the production of a vaccine for parakeets to prevent a disease caused by a paramyxovirus type 3 [J].

Beck, I ;

Gerlach, H ;

Burkhardt, E ;

Kaleta, EF .

VACCINE, 2003, 21 (9-10) :1006-1022

[7] THE SYNERGISTIC NEUTRALIZATION OF RIFT-VALLEY FEVER VIRUS BY MONOCLONAL-ANTIBODIES TO THE ENVELOPE GLYCOPROTEINS [J].

BESSELAAR, TG ;

BLACKBURN, NK .

ARCHIVES OF VIROLOGY, 1992, 125 (1-4) :239-250

[8] TOPOLOGICAL MAPPING OF ANTIGENIC SITES ON THE RIFT-VALLEY FEVER VIRUS ENVELOPE GLYCOPROTEINS USING MONOCLONAL-ANTIBODIES [J].

BESSELAAR, TG ;

BLACKBURN, NK .

ARCHIVES OF VIROLOGY, 1991, 121 (1-4) :111-124

[9] NUCLEOCAPSID-LIKE AND VIRUS-LIKE PARTICLES ASSEMBLE IN CELLS INFECTED WITH RECOMBINANT BACULOVIRUSES OR VACCINIA VIRUSES EXPRESSING THE M-SEGMENTS AND THE S-SEGMENTS OF HANTAAN-VIRUS [J].

BETENBAUGH, M ;

YU, MC ;

KUEHL, K ;

WHITE, J ;

PENNOCK, D ;

SPIK, K ;

SCHMALJOHN, C .

VIRUS RESEARCH, 1995, 38 (2-3) :111-124

[10] Rift valley fever virus lacking the NSs and NSm genes is highly attenuated, confers protective immunity from virulent virus challenge, and allows for differential identification of infected and vaccinated animals [J].

Bird, Brian H. ;

Albarino, Cesar G. ;

Hartman, Amy L. ;

Erickson, Bobbie Rae ;

Ksiazek, Thomas G. ;

Nichol, Stuart T. .

JOURNAL OF VIROLOGY, 2008, 82 (06) :2681-2691

← 1 2 3 4 5 6 →